Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options. J&J announced the FDA’s supplemental approval Tuesday. Previously, Spravato was approved as an add-on therapy
Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases Read More »